Cargando…

Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer – a retrospective analysis: JMTO LC03-02

BACKGROUND: In Japan, high incidences of interstitial lung disease (ILD) and ILD-related deaths have been reported among gefitinib-treated patients with non-small cell lung cancer (NSCLC). We investigated the efficacy of gefitinib, the incidence of ILD and risk factors for ILD in these patients. FIN...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakagawa, Masatsugu, Nishimura, Tsutomu, Teramukai, Satoshi, Tada, Harue, Tanaka, Fumihiro, Yanagihara, Kazuhiro, Furuse, Kiyoyuki, Wada, Hiromi, Fukushima, Masanori
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736173/ https://www.ncbi.nlm.nih.gov/pubmed/19656374 http://dx.doi.org/10.1186/1756-0500-2-157

Ejemplares similares

Lessons from gefitinib-induced interstitial lung disease in Japan: Problems in approval, pharmacovigilance, and regulatory decision-making procedures
por: Nishimura, Tsutomu, et al.
Publicado: (2006)

Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (BRI LC03-01)
por: Kawahara, Masaaki, et al.
Publicado: (2011)

Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02)
por: Hosoe, S, et al.
Publicado: (2003)

A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non‐small cell lung cancer harboring EGFR mutations (JMTO LC12‐01)
por: Asami, Kazuhiro, et al.
Publicado: (2022)

Standard versus low‐dose nab‐paclitaxel in previously treated patients with advanced non‐small cell lung cancer: A randomized phase II trial (JMTO LC14‐01)
por: Takeuchi, Susumu, et al.
Publicado: (2023)

Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03
por: Kishida, Y, et al.
Publicado: (2009)

Correlation between the Lunar Phase and Tail-Lifting Behavior of Lizards (Pogona vitticeps) Exposed to an Extremely Low-Frequency Electromagnetic Field
por: Nishimura, Tsutomu, et al.
Publicado: (2019)

Expression of Thymidylate Synthase in Human Non‐small Cell Lung Cancer
por: Otake, Yosuke, et al.
Publicado: (1999)

Risk factors for lower limb lymphedema after lymph node dissection in patients with ovarian and uterine carcinoma
por: Tada, Harue, et al.
Publicado: (2009)

A randomized phase III study of docetaxel alone versus docetaxel plus S‐1 in patients with previously treated non‐small cell lung cancer: JMTO LC09‐01
por: Atagi, Shinji, et al.
Publicado: (2023)

Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: Results of the JMTO BC08-01 phase II trial
por: NISHIMURA, REIKI, et al.
Publicado: (2013)

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
por: Yokouchi, Hiroshi, et al.
Publicado: (2007)

Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
por: Nagano, Tatsuya, et al.
Publicado: (2011)

Proteomic Biomarkers for Acute Interstitial Lung Disease in Gefitinib-Treated Japanese Lung Cancer Patients
por: Nyberg, Fredrik, et al.
Publicado: (2011)

Choroidal Metastasis of Non-Small Cell Lung Cancer That Responded to Gefitinib
por: Shimomura, Iwao, et al.
Publicado: (2013)

p53 Status Predicts the Efficacy of Postoperative Oral Administration of Tegafur for Completely Resected Non‐small Cell Lung Cancer
por: Tanaka, Fumihiro, et al.
Publicado: (1999)

Summary Session 02 -03 : Shutdown 2012
por: Baird, Simon, et al.
Publicado: (2011)

CERN Bulletin Issue No. 02-03/2010
Publicado: (2010)

EXM-88-02: 17/03/88
por: Martucci, P
Publicado: (1988)

EXM 92-02 26/03/92
por: Daems, G
Publicado: (1992)

The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery
por: Kiba, Takayoshi, et al.
Publicado: (2008)

Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells
por: Tang, Mei-Chuan, et al.
Publicado: (2015)

Gefitinib in Non Small Cell Lung Cancer
por: Costanzo, Raffaele, et al.
Publicado: (2011)

Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases
por: Yano, Yukihiro, et al.
Publicado: (2012)

Gefitinib Treatment Was Unsuccessful for Central Diabetes Insipidus Due to Pituitary Metastasis of Lung Adenocarcinoma
por: Tanaka, Shunnosuke, et al.
Publicado: (2020)

CERN Bulletin Issue No. 01-02-03/2023
Publicado: (2023)

Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients
por: Beom, Seung-Hoon, et al.
Publicado: (2016)

Plasmodium Circumsporozoite Protein Enhances the Efficacy of Gefitinib in Lung Adenocarcinoma Cells by Inhibiting Autophagy via Proteasomal Degradation of LC3B
por: Lu, Xiao, et al.
Publicado: (2022)

Gefitinib-induced skin ulceration in metastatic adenocarcinoma lung
por: Sathyanarayanan, Vishwanath, et al.
Publicado: (2014)

Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating EGFR Mutation: A Case Report
por: Kuwata, Taiji, et al.
Publicado: (2016)

Compte rendu no 02: réunion du 03.10.1995
por: Guillaume, J C, et al.
Publicado: (1995)

PA02.03. Pharmaceutical standardization of Ropya raj rasa
por: Agrawal, Sachin, et al.
Publicado: (2013)

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer
por: Horiike, A, et al.
Publicado: (2011)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
por: Araki, Takuya, et al.
Publicado: (2012)

Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2013)

Clinical significance of gefitinib antitumor activity in patients with lung adenocarcinoma
por: WANG, ZHUN, et al.
Publicado: (2015)

Gefitinib-induced pyogenic granuloma in a patient with lung cancer
por: Sahoo, Satyajeet, et al.
Publicado: (2020)

Effect of aerobic exercise on acquired gefitinib resistance in lung adenocarcinoma
por: Yang, Hong, et al.
Publicado: (2021)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
por: Yuan, Ying, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_k9cgdv2ckoptckcepp30ovjnel